Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
Rajeshwari Sridhara, Olga Marchenko, Qi Jiang et al. · Statistics in Biopharmaceutical Research · 2021
This article provides a summary of discussions from the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section Open Forum organized by the ASA BIOP Statistical Methods in Oncology Scientific Working Group in coordination with the US FDA Oncology Center of Excellence on October 8, 2020. Diverse stakeholders including experts from international regulatory agencies, academicians, and members from the pharmaceutical industry engaged in a debate on Type I error considerations in master protocols with a common control. Although there were concerns in specific situations where Type I error adjustment may be necessary, the panelists agreed that adjustment of Type I error for multiplicity when a common control is used may not be necessary if the hypotheses are inferentially independent.
Cited by 13 works. doi:10.1080/19466315.2021.1906743
Authors
- Rajeshwari Sridhara
- Olga Marchenko
- Qi Jiang
- Richard Pazdur
- Martin Posch
- Mary Weber Redman
- Yevgen Tymofyeyev
- Xiaoyun Nicole Li
- Marc Robert Theoret
- Yuan Li Shen
- Thomas E. Gwise
- Lorenzo Hess
- Michael D Coory
- Andrew Raven
- Naoto Kotani
- Kit C. B. Roes
- Filip Josephson
- Scott M. Berry
- Bruce S. Binkowitz
References
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
- The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review
- Recommendations on multiple testing adjustment in multi-arm trials with a shared control group
- Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials
- Simulation-based sequential Bayesian design
- Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification
- On the need to adjust for multiplicity in confirmatory clinical trials with master protocols
- Commentary on Parker and Weir
- Controlling type I error rates in multi‐arm clinical trials: A case for the false discovery rate
- Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on “The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations”